Oriola Corp
(OHEL:OKDAV)
€
0.97
-0.008 (-0.82%)
Market Cap: 172.14 Mil
Enterprise Value: 165.04 Mil
PE Ratio: 0
PB Ratio: 1.17
GF Score: 65/100 Q2 2024 Oriola Oyj Earnings Call Transcript
Jul 18, 2024 / 07:00AM GMT
Release Date Price:
€1.03
(+1.49%)
Key Points
Positve
- Net sales grew by 13% to EUR 440 million, driven by both distribution and wholesale segments.
- Adjusted EBIT improved by 53% to EUR 5.1 million, indicating better profitability.
- Lower operating expenses and freight costs contributed to profitability improvement.
- The ERP and warehouse management investment is progressing as planned.
- Oriola Corp (FRA:O5O) has a strong financial position with a significant reduction in interest-bearing debt.
Negative
- The Swedish Competition Authority prohibited the sale of Svensk dos AB, impacting strategic plans.
- Volumes in the Finnish market have declined, affecting overall performance.
- Adjusted EBIT in the distribution segment, excluding Swedish dose, declined slightly.
- Kronans Apotek's adjusted EBIT declined significantly from EUR 2.3 million to EUR 0.3 million.
- Equity ratio has declined from 21.2% to 17.2%, indicating a weaker balance sheet.
Tua Stenius;Ornhjelm
Oriola Oyj - Investor Relations and Sustainability Manager
Good morning, everyone, and a warm welcome to Oriola's Q2 results webcast. I am Tua Stenius-Ãrnhjelm from Oriola's Investor Relations. With me today, I have our CEO, Katarina Gabrielson, and CFO, Timo Leinonen.
Timo Leinonen
Oriola Oyj - Chief Financial Officer, Member of the Group Management Team
Good morning.
Tua Stenius;Ornhjelm
Oriola Oyj - Investor Relations and Sustainability Manager
After the presentation, we open up for your questions, and you can start posting them to us already during the presentation. As a kind reminder, in the Q&A, we will focus on questions relating to Oriola's business and financial development. We can and will answer questions on Kronans Apotek, but only within a limited scope.
Finally, please note that we are also recording this webcast, and the recording will be available on our website later today. Before handing over to Katarina, here is the customer
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot